CD4 and neoplasm: This result in antigen presentation onto the MHC-I/II (immunogenic tumor epitopes) via T-cell receptors (TCRs recognize most foreign and activated tumor epitopes and help the immune system to decide the best line-targets) thereby leading to activation of CD4 and CD8+ T-cells.